Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
(Q84605146)
Watch
English
Ovarian cancer
scientific article published on 28 September 2009
In more languages
default for all languages
No label defined
No description defined
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
19793610
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19793610%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 February 2020
title
Ovarian cancer
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
19793610
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19793610%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 February 2020
author
Bryan T. Hennessy
series ordinal
1
object named as
Bryan T Hennessy
1 reference
stated in
Europe PubMed Central
PubMed publication ID
19793610
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19793610%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 February 2020
author name string
Robert L Coleman
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed publication ID
19793610
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19793610%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 February 2020
Maurie Markman
series ordinal
3
1 reference
stated in
Europe PubMed Central
PubMed publication ID
19793610
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19793610%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 February 2020
language of work or name
English
0 references
publication date
28 September 2009
1 reference
stated in
Europe PubMed Central
PubMed publication ID
19793610
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19793610%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 February 2020
published in
The Lancet
1 reference
stated in
Europe PubMed Central
PubMed publication ID
19793610
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19793610%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 February 2020
volume
374
1 reference
stated in
Europe PubMed Central
PubMed publication ID
19793610
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19793610%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 February 2020
issue
9698
1 reference
stated in
Europe PubMed Central
PubMed publication ID
19793610
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19793610%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 February 2020
page(s)
1371-1382
1 reference
stated in
Europe PubMed Central
PubMed publication ID
19793610
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19793610%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 February 2020
cites work
Cancer of the ovary
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Characterization of BRCA1 and BRCA2 mutations in a large United States sample
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Declining trends of epithelial ovarian cancer in California.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Temporal trends in ovarian cancer: incidence and mortality across Europe
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Incessant ovulation--a factor in ovarian neoplasia?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Transcriptional profiling develops molecular signatures for ovarian tumors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ovarian cancer: homeobox genes, autocrine/paracrine growth, and kinase signaling
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mutation of the PIK3CA gene in ovarian and breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
PIK3CA is implicated as an oncogene in ovarian cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ovarian cancer: linking genomics to new target discovery and molecular markers--the way ahead
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Epigenetic silencing of the imprinted gene ZAC by DNA methylation is an early event in the progression of human ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Early detection of ovarian cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Granulosa cell tumor of the ovary
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Survival and prognostic factors of women with advanced ovarian cancer and complete response after a carboplatin–paclitaxel chemotherapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Survival and prognostic factors in early-stage epithelial ovarian carcinoma treated with taxane-based adjuvant chemotherapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Early symptoms of ovarian cancer: a case-control study without recall bias.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ovarian adenocarcinoma presenting with the sign of Leser-Trélat
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ultrasound evaluation of pelvic masses: predictors of malignancy for the general gynecologist
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ultrasound characteristics of different types of adnexal malignancies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ovarian cancer: detection and radiologic staging.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Staging Laparotomy in Early Ovarian Cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Does systematic lymphadenectomy have a benefit on survival of suboptimally debulked patients with stage III ovarian carcinoma? A DEGOG* Study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes Only in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
"Optimal" cytoreduction for advanced epithelial ovarian cancer: a commentary
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Diaphragm resection for ovarian cancer: technique and short-term complications
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Systematic review of adjuvant care for women with Stage I ovarian carcinoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatme
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada [...]
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The role of maintenance therapy and novel taxanes in ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Intraperitoneal chemotherapy in ovarian cancer remains experimental
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Intraperitoneal chemotherapy for ovarian cancer: 2009 goals.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer: A critical need for an evidence-based evaluation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Secondary surgical cytoreduction for advanced ovarian carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pharmaceutical management of ovarian cancer : current status
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Role of surgery in ovarian carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Why did p53 gene therapy fail in ovarian cancer?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Development of antiangiogenic agents for ovarian cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961338-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0140-6736(09)61338-6
1 reference
stated in
Europe PubMed Central
PubMed publication ID
19793610
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19793610%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 February 2020
PubMed publication ID
19793610
1 reference
stated in
Europe PubMed Central
PubMed publication ID
19793610
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19793610%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 February 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit